I hope this truly is a breakthrough and does more good than harm. As a child I had near daily migraines. In 2002 I entered into an earlier CGRP blocker study to extremely ill effect. I took two pills morning and night. After two days I woke up completely blind. I was lucky it only lasted for three days (I was instructed to immediately discontinue use of the drug, preventing any long term damage). The trial was called off shortly after - if memory serves, out of ~100+ participants in my age group, about five had the same symptoms.
As the article mentions, there’s a risk around toxicity. The approved distribution, dosage, and delivery seems to be an entirely different process from 15+ years ago, so here’s to the best. But, there’s really not a single measurement of residual peptide buildup throughout the entire study.
I worry about long term buildup of proinflammatory mediators that could eventually strike back fast and hard with long term ocular nerve damage; a similar effect as the earlier drug iterations of a higher toxicity.
As the article mentions, there’s a risk around toxicity. The approved distribution, dosage, and delivery seems to be an entirely different process from 15+ years ago, so here’s to the best. But, there’s really not a single measurement of residual peptide buildup throughout the entire study.
I worry about long term buildup of proinflammatory mediators that could eventually strike back fast and hard with long term ocular nerve damage; a similar effect as the earlier drug iterations of a higher toxicity.